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Presenilins 1 and 2 (PS1/2), causative molecules for familial Alzheimer’s disease (FAD), are 
multipass transmembrane proteins localized predominantly in the endoplasmic reticulum (ER) 
and Golgi apparatus. Heteromeric protein complexes containing PS1/2 are thought to 
participate in several functions, including intramembrane proteolysis mediated by their 
γ-secretase activities. Previous studies have shown that PS1/2 are also involved in the regulation 
of apoptotic cell death, although the underlying mechanism remains unknown. Here, we 
demonstrate that FKBP38, an immunophilin family member residing in the mitochondrial 
membrane, is an authentic PS1/2-interacting protein. PS1/2 and FKBP38 form macromolecular 
complexes together with anti-apoptotic Bcl-2. PS1/2 promote the degradation of FKBP38 and 
Bcl-2, and sequester these proteins in the ER/Golgi compartments, thereby inhibiting 
FKBP38-mediated mitochondrial targeting of Bcl-2 via a γ-secretase-independent mechanism. 
Thus, PS1/2 increase the susceptibility to apoptosis by antagonizing the anti-apoptotic function 
of FKBP38. In contrast, C-terminal fragments of caspase-processed PS1/2 redistribute Bcl-2 to 
the mitochondria by abrogating the activity of full-length PS1/2, resulting in a 
dominant-negative anti-apoptotic effect. In cultured cells and mutant PS1-knockin mouse brains, 
FAD-linked PS1/2 mutants enhance the pro-apoptotic activity by causing a more efficient 
reduction in mitochondrial Bcl-2 than wild-type PS1/2. These results suggest a novel molecular 
mechanism for the regulation of mitochondria-mediated apoptosis by competition between 
PS1/2 and FKBP38 for subcellular targeting of Bcl-2. Excessive pro-apoptotic activity of PS1/2 
may play a role in the pathogenesis of FAD. 
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INTRODUCTION 
Apoptotic cell death is an essential process required for development and maintenance of 
normal tissues, but it is also involved in various pathological conditions. Mitochondria play a pivotal 
role in the intrinsic pathway of apoptosis, wherein various apoptotic stimuli converge to cause 
increased permeability of the outer mitochondrial membrane, resulting in the release of mitochondrial 
apoptogenic proteins, such as cytochrome c and Smac/Diablo, into the cytosol (1). Mitochondrial 
membrane permeability is negatively and positively regulated by anti-apoptotic and pro-apoptotic 
members of the Bcl-2 family, respectively (2, 3). The ratio of anti- to pro-apoptotic members and the 
mitochondrial localization critically influence the susceptibility to apoptosis (2-4). 
Alzheimer’s disease (AD), the most common cause of dementia in the elderly, is 
neuropathologically characterized by prominent neuronal loss with astrogliosis and by the appearance 
of extracellular amyloid plaques and intracellular neurofibrillary tangles in the cerebral cortex. 
Excessive accumulation of amyloid β (Aβ) peptide, which is the major constituent of amyloid plaques, 
is thought to trigger a pathological cascade leading to neurodegeneration in AD. However, the chronic 
progression of the degeneration in AD has made it difficult to elucidate the mechanism of neuronal 
loss. Although the contribution of apoptosis to neuronal death in AD brains is still controversial, a 
number of previous reports have demonstrated the potential involvement of Aβ peptide and its 
precursor protein in the induction or regulation of apoptotic neuronal death (reviewed in 5-7). In 
addition, circumstantial evidence of apoptosis in postmortem brain tissues has supported the 
hypothesis that an apoptotic mechanism plays a role in the neurodegeneration in AD (8, 9). 
 Mutations in presenilins 1 and 2 (PS1/2) are responsible for the majority of autosomal 
dominant forms of familial Alzheimer’s disease (FAD) (10). These two proteins are highly 
homologous and consist of eight transmembrane domains and a large hydrophilic loop between 
transmembrane domains 6 and 7. Presenilins are ubiquitously expressed, and undergo physiological 
endoproteolytic cleavage, yielding N- and C-terminal fragments (NTF and CTF, respectively). The 
accumulation of these proteolytic derivatives in vivo is tightly regulated and saturable (11), suggesting 
that constitutive levels of expression are crucial for cell function.  
Independent of the original cloning of PS1/2 as genes causing FAD, functional screening 
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identified a truncated mouse homologue of PS2 (referred to as ALG-3) as an apoptosis-linked 
molecule (12). Overexpression of PS2 in diverse cell types leads to enhanced susceptibility to various 
apoptotic stimuli, whereas suppression of PS2 expression by antisense RNA reduces the apoptotic 
susceptibility of PC12 cells (13, 14). Moreover, FAD-linked mutations of both PS1 and PS2 potentiate 
their pro-apoptotic properties in cultured cells and in neurons from mutant PS1-knockin mice (13, 
15-23). Meanwhile, PS1/2 are cleaved by activated caspase-3 family proteases during apoptosis in 
cultured cells (24). Similar to the ALG-3 polypeptide, overexpression of polypeptides corresponding 
to the C-terminal PS1/2 fragments generated by caspase cleavage inhibits apoptosis (25, 26). These 
findings strongly suggest that PS1/2 are involved in the regulation of apoptosis under physiological 
and pathological conditions. However, the molecular mechanism underlying these observations 
remains to be elucidated. 
In addition to regulation of apoptosis, PS1/2 have been implicated as unique aspartyl 
proteases, referred to as γ-secretase, that mediate the intramembrane cleavage of various type-I 
transmembrane proteins (27), scaffolding proteins that facilitate the phosphorylation of β-catenin (28), 
and modulators of cellular calcium homeostasis (29). PS1/2 proteins become stabilized and functional 
after assembly into each heteromeric macromolecular complex. The essential components of PS 
complexes include at least three membrane proteins, nicastrin, APH-1 and PEN-2. These complexes 
participate in a variety of functions, probably by interacting with multiple sets of effector proteins. 
Here, we identified FK506-binding protein 38 (FKBP38) as a novel PS-binding partner. 
Among FKBP family members, FKBP38 is unique in displaying neither an affinity for FK506 nor 
peptidyl-prolyl cis/trans-isomerase activity (30-32). High-molecular weight immunophilins, including 
FKBP38, FKBP51, FKBP52, and CyP40, are structurally characterized by tetratricopeptide repeats 
(TPRs) that mediate protein-protein interaction (30, 31, 33). Additionally, FKBP38 has a 
transmembrane domain at its C-terminus and is predominantly localized in the mitochondrial 
membrane (33). A recent study revealed that FKBP38 inhibits apoptosis by targeting and anchoring 
anti-apoptotic Bcl-2 to the mitochondria (33). Here, we demonstrate that the pro-apoptotic function of 
PS1/2 is due to competition with the anti-apoptotic activity of FKBP38. Caspase-processed C-terminal 
fragments of PS1/2 abrogate the antagonizing action of full-length (FL) PS1/2 on FKBP38, exhibiting 
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a dominant-negative anti-apoptotic effect, whereas FAD-linked mutations of PS1/2 cause enhanced 
inhibition of FKBP38 activity. 
RESULTS 
PS1/2 specifically interact with FKBP38 
To clarify the molecular basis by which PS1/2 regulate apoptosis, we first searched for 
proteins that interact with the PS1 CTF, a highly conserved region that is likely responsible for the 
modulation of apoptosis (25). We performed a yeast two-hybrid screen of a HeLa cell cDNA library 
using the human PS1 C-terminal sequence (residues 351-467) as bait. We isolated seven positive 
clones by screening 3.5 × 106 transformants and confirmed the interaction by a yeast mating assay on a 
high stringency medium. DNA sequencing and BLAST searches revealed that two of these clones 
encoded full-length FKBP38. 
 Binding between PS1/2 and FKBP38 in mammalian cells was then examined. Human 
FKBP38 fused at its C-terminus to a Myc epitope tag (FKBP38-Myc) was transiently transfected into 
human embryonic kidney 293 (HEK293) cells along with PS1 or PS2. We found that PS1 and PS2 
coimmunoprecipitated with FKBP38-Myc but not with other TPR-containing immunophilins, 
including CyP40-Myc, FKBP51-Myc, and FKBP52-Myc (Fig. 1A). Although PS1 and PS2 were 
expressed at similar levels, in all experiments, larger amounts of PS2 coprecipitated with 
FKBP38-Myc when compared with PS1. In addition, endogenous PS1 and PS2 coprecipitated with 
FKBP38 in HEK293 cell lysates (data not shown). 
To confirm a physiological interaction between PS1/2 and FKBP38, we examined their 
endogenous binding in lysates of murine brains. We found that FKBP38 coprecipitated with both PS1 
and PS2 (Fig. 1B). The specificity of this interaction was supported by the lack of binding to calnexin, 
an endoplasmic reticulum (ER)-associated protein, as well as by confirmation of binding by Bcl-2, a 
known FKBP38-binding protein (33). Similar to the HEK293 experiments, a larger amount of 
FKBP38 coprecipitated with PS2 than with PS1. 
We next assessed the binding of PS1/2 to a dominant-negative mutant, FKBP38ΔTM, that 
lacks the transmembrane domain and the ability to localize in the mitochondria (33). We found that 
similar amounts of haemagglutinin A-tagged FKBP38ΔTM (FKBP38ΔTM-HA) and full-length 
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FKBP38-HA were detected in immunoprecipitates with an anti-PS1 CTF or anti-PS2 CTF antibody 
(Fig. 1C). Together with the results of the two-hybrid screen, this indicates that PS1/2 CTFs interact 
with the N-terminal region of FKBP38, which contains TPR domains (30, 31). 
Both PS1 and FKBP38 have been reported to associate with Bcl-2 (33, 34). To investigate 
the binding mode between these three proteins, we performed coimmunoprecipitation assays with 
PS1/2- and/or FKBP38-depleted cell lysates. As described previously (33), RNA interference (RNAi) 
using a small interfering RNA (siRNA) duplex successfully reduced the endogenous expression of 
FKBP38 in mouse embryonic fibroblasts (MEFs). In agreement with prior reports (33, 34), anti-Bcl-2 
antibody coprecipitated PS1, PS2, and FKBP38 in native cell lysates (Fig. 1D). Whereas FKBP38 
coprecipitated with Bcl-2 in lysates from PS1- and PS2-double knockout (PS1/2-null) cells, only trace 
levels of PS1 and PS2 coimmunoprecipitated with Bcl-2 in lysates from FKBP38 knockdown cells 
(Fig. 1D). This result suggests that association of PS1/2 with Bcl-2 is largely mediated through their 
binding to FKBP38. 
PS1/2, FKBP38, and Bcl-2 are components of multiprotein complexes 
Based on the ability of PS1/2 to associate with FKBP38 and Bcl-2, we suspected that these 
proteins are components of heteromeric complexes. We investigated this possibility using glycerol 
velocity gradient centrifugation analysis of native HEK293 cell extracts (Fig. 2A). As previously 
reported (35), NTF and CTF of endogenous PS1 formed complexes of ~200 to 400 kDa. FKBP38 was 
detected in a molecular weight range above 200 kDa, which is substantially higher than that of the 38 
kDa monomer. Bcl-2 is distributed in a range between 60 and 300 kDa. FKBP38 and Bcl-2 partially 
overlapped with PS1 in fractions 6 to 8, suggesting that restricted subsets of these proteins bind with 
PS1 (Fig. 2A). Because PS2 is expressed at a low level in native cells, we used HEK293 cells stably 
transfected with PS2 to examine its complex formation. In this system, the relative molecular weight 
of PS2 CTF-containing complex was similar to that of the PS1 complex, whereas uncleaved PS2 
holoprotein was distributed over the lower molecular weight range (Fig. 2A). To further confirm the 
binding between these proteins, we performed coimmunoprecipitation of fractionated samples. We 
found that both FKBP38 and Bcl-2 coprecipitated with PS1 or PS2 in fractions 6 to 8 (Fig. 2B and 
data not shown), supporting the notion that PS1/2 form complexes with FKBP38 and Bcl-2. 
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Deletion of PS1/2 reduces susceptibility to mitochondria-mediated apoptosis 
A recent study has revealed that FKBP38 is an anti-apoptotic protein (33). Therefore, it is 
possible that the interaction between PS1/2 and FKBP38 is related to the regulation of apoptosis. We 
first estimated the susceptibility to apoptosis of MEFs from PS1- and/or PS2-knockout mice. After 
treatment with apoptotic agents, cell viability and apoptosis were quantified by 
3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide (MTT) conversion and annexin 
V/propidium iodide (PI) staining, respectively. PS1-null, PS2-null, and PS1/2-null MEFs were 
significantly less sensitive than native MEFs to induction of apoptotic cell death by staurosporine or 
A23187 (Fig. 3A and B). The effect of PS2 deletion was more potent than that of PS1 deletion (p < 
0.001 by one-way ANOVA with Dunnett’s post-hoc test), and the effects of PS1 and PS2 deletion 
were additive. A similar result was obtained when these MEFs were treated with rapamycin (0.1 
µg/ml) or etoposide (20 µM) (data not shown). In subsequent experiments, we used PS1/2-null MEFs 
to avoid compensation for the loss of either of the two proteins. 
We further examined the contribution of PS1/2 to apoptosis by assessing its effects on 
mitochondria-mediated apoptosis signaling, which involves cytochrome c release from the 
mitochondria to the cytosol. As shown in Fig. 3C, under basal conditions (vehicle control), 
cytochrome c was not detected in the cytosol fraction from either native or PS1/2-null MEFs. A 24-h 
treatment with staurosporine or A23187 induced translocation of cytochrome c from the membrane to 
the cytosol in native MEFs. This translocation was less prominent in PS1/2-null MEFs, suggesting that 
PS1/2 deletion results in decreased sensitivity to mitochondria-mediated apoptosis. 
PS1/2 promote the degradation of FKBP38 and Bcl-2 
PS1/2 are required for the proper expression of certain PS-binding proteins. For example, 
PS1/2 deletion downregulates the accumulation of PEN-2 and the maturation of nicastrin (27). In 
contrast, immunoblotting unexpectedly showed that the relative band intensities for FKBP38 and 
Bcl-2 in PS1/2-null MEFs increased by ~81% and ~58%, respectively, when compared with native 
MEFs (mean of three independent blots; p < 0.01 by Student’s-t test; Fig. 4A). Semi-quantitative 
RT-PCR revealed that native and PS1/2-null MEFs expressed similar levels of FKBP38 and Bcl-2 
mRNA (Fig. 4B). However, as shown in Fig. 4C, the half-life of FKBP38 protein in the presence of 
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cycloheximide was significantly longer in PS1/2-null than in native MEFs (mean ± SD; 17.2 ± 0.9 h vs. 
10.5 ± 0.7 h [n = 4], respectively; p < 0.01 by Student’s-t test). A similar increase in the half-life of 
Bcl-2 protein in PS1/2-null MEFs was observed (mean ± SD; 35.7 ± 1.9 h vs. 23.4 ± 1.3 h [n = 4], 
respectively; p < 0.01 by Student’s-t test). Transfection of PS1 or PS2 into PS1/2-null MEFs 
decreased the half-lives of these proteins (data not shown). Finally, pulse-chase experiments 
confirmed that the rate of FKBP38 translation was equivalent in native and PS1/2-null MEFs but that 
there was a clear delay in FKBP38 degradation in PS1/2-null MEFs (Fig. 4D). A similar result was 
obtained for Bcl-2 (data not shown). Taken together, these results suggest that PS1/2 destabilize 
FKBP38 and Bcl-2 proteins, decreasing their steady-state levels without affecting the rates of 
transcription or translation. 
FKBP38 is not a substrate for the γ-secretase activity of PS1/2 complexes 
PS1/2 are catalytic components of γ-secretase complexes that mediate intramembrane 
cleavage of amyloid β-precursor protein (APP) and several other type I membrane proteins (27). We 
therefore tested the possibility that PS1/2 degrade FKBP38 through their γ-secretase activities. We 
first checked for the release of cleavage products from the membrane, but we were unable to detect 
any discernible bands in the cytosol and cell culture medium by immunoblotting (Fig. 5A). Treatment 
of cells with the potent γ-secretase inhibitors DFK167, DAPT, or L-685,458 (36) caused accumulation 
of APP CTF, which is a direct substrate for γ-secretase. However, these inhibitors did not affect the 
accumulation level of FKBP38 (Fig. 5B). To detect size reduction by intramembrane cleavage, we 
generated a FKBP38 construct fused to the N-terminus of green fluorescent protein (GFP). Anti-GFP 
immunoblotting of HEK293 cells transfected with this fusion protein and treated with or without 
DFK167 revealed only a 60-kDa band representing the intact fusion protein (Fig. 5C). Together with 
the prediction that FKBP38 is a type II membrane protein (33), these results suggest that FKBP38 is 
not a substrate for γ-secretase. 
PS1/2 sequester FKBP38 and Bcl-2 in the ER/Golgi compartments 
The anti-apoptotic function of FKBP38 is mediated by targeting and anchoring Bcl-2 to 
mitochondria (33). We investigated whether PS1/2 alter the subcellular localization of FKBP38 and 
Bcl-2. Under physiological conditions, the majority of FKBP38 and Bcl-2 is localized in the 
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mitochondria, while a smaller amount is found in the ER/Golgi and nuclear envelope (33, 37). In 
contrast, PS1/2 is predominantly distributed in the ER/Golgi and, to a lesser extent, in the plasma 
membrane, nuclear envelope, and mitochondria (38-40). Double fluorescence staining revealed that 
the mitochondrial localization of FKBP38 was more prominent in PS1/2-null than in native MEFs (Fig. 
6A, yellow signals in the merged images). A similar increase in the mitochondrial Bcl-2 was observed 
in PS1/2-null MEFs (Fig. 6B). 
To confirm this result, we employed subcellular fractionation of vesicular organelles on an 
iodixanol gradient, which considerably separated the mitochondria (fractions 1 to 5) from the 
ER/Golgi (fractions 5 to 10) (Fig. 6C). As expected, in native MEFs, PS1 CTF were identified in the 
ER/Golgi fractions, whereas FKBP38 was recovered from both the mitochondrial and ER/Golgi 
fractions. In contrast, in PS1/2-null MEFs, FKPB38 was detected only in mitochondria-rich fractions. 
Similarly, in the native cells, there were two broad Bcl-2 peaks, corresponding to the mitochondrial 
and ER/Golgi fractions, whereas in PS1/2-null MEFs, the ER/Golgi peak disappeared and the 
mitochondrial peak increased (Fig.6C). Together with immunocytochemical studies, these 
observations imply that, under normal conditions, PS1/2 sequester FKBP38 and Bcl-2 in the ER/Golgi 
compartments, reducing their levels in mitochondria. Consistent with the result that PS1/2 do not bind 
to CyP40, FKBP51 or FKBP52 (Fig. 1A), Hsp90 heteromeric complexes, which contain these 
immunophilins (41), were not associated with membranous organelles in the absence or presence of 
PS1/2 (data not shown). 
In addition, we investigated the effect of FKBP38 depletion on the subcellular localization 
of Bcl-2. When FKBP38 was depleted in native MEFs by RNAi, Bcl-2 was markedly diminished in 
the mitochondrial fractions and was predominantly distributed in the ER/Golgi fractions (Fig. 6D, left 
panel). As predicted by our coimmunoprecipitation results, which suggested that PS1/2 associate with 
Bcl-2 via FKBP38 (Fig. 1D), FKBP38 knockdown by RNAi abrogated the effect of PS1/2 on the 
subcellular distribution of Bcl-2. Thus, FKBP38 depletion in PS1/2-null MEFs resulted in a similar 
pattern of Bcl-2 distribution as that found in FKBP38-depleted native MEFs (Fig. 6D).  
Promotion of apoptosis by PS1/2 corresponds with a reduction in mitochondrial Bcl-2 
We reasoned that the pro-apoptotic activity of PS1/2 might be mediated through their 
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binding to FKBP38 and the subsequent reduction of mitochondrial Bcl-2. PS1/2 deletion decreased the 
apoptotic susceptibility, whereas overexpression of wild-type (WT) PS2 significantly sensitized cells 
to staurosporine-induced apoptosis when compared with native cells (Fig. 7A, compare PS1/2-null or 
WT PS2-overexpressing with native MEFs). The total amount of FKBP38 or Bcl-2 inversely 
correlated with the level of PS1/2 (Fig. 7B and see also 42 and 43). Furthermore, subcellular 
fractionation revealed that PS1/2 deletion increased Bcl-2 in the mitochondrial fractions (Fig. 6C), 
whereas PS2 overexpression reduced mitochondrial Bcl-2 by sequestering it in the ER/Golgi (Fig. 7C, 
compare WT PS2-overexpressing with native MEFs). Exogenous overexpression of FKBP38 could 
reduce the pro-apoptotic effect of co-overexpressed PS2 by redistributing Bcl-2 from the ER/Golgi to 
the mitochondria (Figs. 7A and C, compare WT PS2 + FKBP38-overexpressing with WT 
PS2-overexpressing MEFs). In contrast, expression of C-terminally truncated PS2 (residues 1-350), 
which does not bind with FKBP38, neither enhanced the apoptotic susceptibility nor altered the 
localization of Bcl-2 in native or PS1/2-null MEFs (data not shown). Furthermore, when 
overexpressing a dominant-negative mutant FKBP38ΔTM, which markedly increased the apoptotic 
susceptibility by shifting Bcl-2 to the cytosol (33), or when FKBP38 was depleted by RNAi, native 
and PS1/2-null MEFs exhibited a similar apoptosis susceptibility and Bcl-2 localization (Fig. 6D, and 
data not shown). These results indicate that the promotion of apoptosis by PS2 is mediated by its 
binding to FKBP38 and corresponds with a reduction in mitochondrial Bcl-2. PS1/2 appear to compete 
with FKBP38 for subcellular targeting of Bcl-2. 
We next examined the anti-apoptotic activity of a polypeptide corresponding to 
caspase-3-processed PS2 CTF (PS2 CTFCAS; corresponding to residues 329-448 of PS2 along with an 
initiating methionine) (25, 26). Upon iodixanol fractionation, exogenous PS2 CTFCAS was more 
broadly distributed than the physiologically processed PS2 CTF (Fig. 7D). Overexpression of PS2 
CTFCAS in native MEFs significantly decreased the sensitivity to staurosporine-induced apoptosis and 
shifted Bcl-2 from the ER/Golgi to the mitochondrial fractions (Figs. 7A and C, compare PS2 
CTFCAS-overexpressing with native MEFs). PS2 CTFCAS-overexpressing MEFs had a similar viability 
and Bcl-2 localization as PS1/2-null MEFs, suggesting that PS2 CTFCAS abrogated the pro-apoptotic 
activity of endogenous PS1/2 by impeding sequestration of Bcl-2 in the ER/Golgi. Overexpression of 
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PS2 CTFCAS also caused a reduction in endogenous PS1/2 coimmunoprecipitating with FKBP38 (data 
not shown). These results suggest that exogenous PS2 CTFCAS, which contains the FKBP38 binding 
domain but presumably lacks the ability to sequester FKBP38 and Bcl-2 in the ER/Golgi, compete 
with endogenous PS1/2 for binding to FKBP38, thus resulting in a dominant-negative effect. 
Consistent with a previous report (25), similar results were obtained with polypeptides corresponding 
to the physiological CTF of PS2 (residues 298-448) (data not shown). 
FAD-linked mutations of PS1/2 enhance the sequestration of Bcl-2 in the ER/Golgi 
We further investigated the pro-apoptotic effects of FAD-linked mutants (N141I- and 
M239V-PS2). In agreement with prior reports (15, 16, 43), the apoptosis susceptibility of PS1/2-null 
MEFs was more enhanced when they overexpressed FAD-linked PS2 than when they overexpressed 
WT PS2 (Fig. 7A, compare N141I- or M239V-PS2-overexpressing with WT PS2-overexpressing 
MEFs). In addition, N141I-PS2 sequesters more Bcl-2 in the ER/Golgi fractions than WT PS2 (Fig. 
7C, compare N141I-PS2-overexpressing with WT PS2-overexpressing MEFs), although the 
expression levels and subcellular distribution of N141I- and WT PS2 were equivalent (Fig. 7D). 
Similar results were obtained with FAD-linked (I143F and L392V) PS1 (data not shown). 
To exclude the possibility that this mutational effect was caused by overexpression of 
mutant PS, we performed iodixanol fractionation of brain homogenates from FAD-linked mutant 
(I213T) PS1-knockin mice (44). Primary cultured neurons from FAD-linked mutant PS1-knockin 
mice have been reported to exhibit the enhanced susceptibility to apoptosis induced by various stimuli 
(20, 45). As shown in Fig. 7E, I213T mutation obviously shifted Bcl-2 distribution from the 
mitochondria to the ER/Golgi fractions in a gene dosage-dependent manner. This suggests that a 
physiological level of FAD-linked mutant PS1 can modify the subcellular distribution of Bcl-2. 
The pro-apoptotic function of PS2 is independent of γ-secretase activity 
Finally, to assess the relationship between the pro-apoptotic function of PS1/2 and 
γ-secretase activity, we treated native MEFs with DFK167, DAPT, or L-685,458. We found that these 
γ-secretase inhibitors had no effect on the localization of Bcl-2 (data not shown). We also examined 
the effects of D366A-PS2, which has no γ-secretase activity, in PS1/2-null MEFs. Subcellular 
distribution of transfected D366A-PS2 was similar to that of WT PS2 FL (Fig. 7D). When compared 
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with WT PS2-transfected MEFs, there were no differences in apoptotic susceptibility or subcellular 
localization of Bcl-2 (Figs. 7A and C, compare D366A-PS2-overexpresing with WT 
PS2-overexpressing MEFs), suggesting that the pro-apoptotic function of PS2 is independent of 
γ-secretase activity. 
DISCUSSION 
 Using a yeast two-hybrid screen and other supportive methods, we identified FKBP38 as a 
directly interacting partner of PS1/2 proteins. Comparative studies using native and PS1/2-null cells 
disclosed the consequences of this interaction, although a relatively small pool of FKBP38 appeared to 
bind with PS1/2. We showed that the ablation of PS1/2 led to a slower turnover of FKBP38 protein 
and a more restricted localization of FKBP38 in the mitochondria. Thus, PS1/2 facilitate the 
degradation of FKBP38 in a γ-secretase-independent fashion, and sequester FKBP38 in the ER/Golgi 
compartments, thereby reducing the amount of mitochondrial FKBP38. 
 Previous reports have shown an interaction between PS1 and Bcl-2 as well as between 
FKBP38 and Bcl-2 (33, 34). We observed that these membrane proteins are incorporated into 
macromolecular complexes. Bcl-2 coimmunoprecipitated with FKBP38 even in the absence of PS1/2, 
but that a very small amount of Bcl-2 coprecipitated with PS1 or PS2 in FKBP38-depleted cell lysates. 
This result suggests that PS1/2 are associated with Bcl-2 mainly by binding with FKBP38, although 
our result does not completely eliminate the possibility that PS1/2 have a weak binding affinity to 
Bcl-2. This is concordant with the previous report showing that Bcl-2 coimmunoprecipitated with PS1 
in Bcl-2-overexpressing but not in native H4 neuroglioma cells (34). PS1/2 downregulate the 
accumulation level of Bcl-2, and sequester Bcl-2 in the ER/Golgi compartments in an expression 
level-dependent manner. As a result, the amount of mitochondrial Bcl-2 increases in the absence of 
PS1/2 and decreases when overexpressing PS1/2. 
 Our results indicate that PS1/2 modulate the susceptibility to apoptosis by regulating the 
subcellular localization of Bcl-2 via binding to FKBP38. The representative anti-apoptotic members of 
the Bcl-2 family, Bcl-2 and Bcl-XL, primarily function on the outer mitochondrial membrane 
(reviewed in 2-4). Bcl-XL has a targeting signal for the mitochondria, but Bcl-2 does not (46). Recent 
studies have suggested that binding to anchor proteins residing in specific compartments is an 
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important determinant of the subcellular distribution of Bcl-2 and Bcl-XL. Thus, FKBP38 is 
responsible for the mitochondrial localization of Bcl-2 and Bcl-XL (33), whereas overexpression of 
reticulon family members (i.e., RTN-XS and NSP-C) sensitizes cells to apoptosis by increasing the 
localization of Bcl-XL on the ER (47). Exogenously expressed RTN-XS also induces the localization of 
Bcl-2 on the ER to a lesser extent (47). Our results indicate that PS1/2 shift Bcl-2 from the 
mitochondria to the ER/Golgi in an expression level-dependent manner. The pro-apoptotic activity of 
PS1/2 correlates well with the reduction in mitochondrial Bcl-2, and this can be antagonized by 
overexpression of FKBP38. Thus, PS1/2 compete with FKBP38 for regulation of the amount of 
mitochondrial Bcl-2, and this competition probably depends on the relative levels of FKBP38 and 
PS1/2. The more potent effect of PS2 (relative to PS1) may be due to its higher affinity for FKBP38 
(see Figs. 1A, 1B, 3A and 3B). PS1/2 have been reported to bind to Bcl-XL as well as Bcl-2 (48), but 
we could not detect obvious effects of PS1/2 on the subcellular localization of Bcl-XL (data not 
shown). These results indicate that PS1/2 and reticulon family members are predominantly responsible 
for the ER/Golgi localization of Bcl-2 and Bcl-XL, respectively. 
PS1/2 are substrates for effector caspases that execute the apoptotic death process. Thus, 
PS1/2 undergo alternative endoproteolysis during apoptosis, which can be blocked by zDEVD-fmk, an 
inhibitor of caspase-3 family proteases (24, 25). This cleavage yields C-terminal polypeptides, PS1/2 
CTFsCAS, which are shorter than physiologically processed CTFs (PS1/2 CTFsPHY). Our results indicate 
that PS1/2 CTFsCAS competes with FL PS1/2 for binding to FKBP38 and thereby acts as a 
dominant-negative inhibitor of Bcl-2 sequestration in the ER/Golgi. Thus, the generation of PS1/2 
CTFsCAS by activated caspases may constitute a negative feedback loop in apoptosis signaling. Similar 
to PS2 CTFCAS, PS2 CTFPHY exhibited anti-apoptotic activity (25). However, PS1/2 CTFsPHY are 
incorporated into PS complexes together with PS1/2 NTFs immediately after the physiological 
cleavage, and the monomeric PS1/2 CTFsPHY cannot be detected in normal cells (35). Therefore, PS1/2 
CTFsPHY are unlikely to contribute to the anti-apoptotic activity. 
Several apoptosis signaling events have been implicated in PS-induced apoptosis, which 
include activation of p53 (23, 49) or p38 mitogen activated protein kinases (50), downregulation of 
Akt/protein kinase B signaling (51) or unfolded protein response signaling (52), destabilization of 
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β-catenin (53), and perturbed calcium homeostasis (17, 54). PS1/2 might be directly or indirectly 
involved in multiple pathways for cell death. However, we have concluded that the pro-apoptotic 
activity of PS1/2 mainly dependents on their binding with FKBP38 and a reduction of mitochondrial 
Bcl-2 for the following reasons. First, overexpression of FKBP38 could neutralize the pro-apoptotic 
activity of PS1/2 by redistributing Bcl-2 from the ER/Golgi to the mitochondria. Second, in 
FKBP38-deleted cells, PS1/2 did not have the pro-apoptotic activity and effect on localization of Bcl-2. 
Third, PS2 CTFCAS decreased the sensitivity to apoptosis and simultaneously shifted Bcl-2 from the 
ER/Golgi to the mitochondria in a dominant-negative manner. Fourth, C-terminally truncated PS2 that 
lacks the binding site for FKBP38 had no effect on apoptosis susceptibility and Bcl-2 localization. We 
thought that the inactivity of this truncated PS2 was not only due to instability of this polypeptide, 
because transfected PS2 CTF had the anti-apoptotic activity in spite of the similar instability (55). 
PS complexes are involved in many vital functions through binding to various proteins in 
addition to forming the γ-secretase complexes together with three essential components. The absence 
of PS1/2 results in the downregulation of the essential component proteins (27), although PS1/2 
binding does not lead to alteration in the accumulation levels of many other interacting proteins. By 
contrast, we found that PS1/2 destabilize FKBP38 and Bcl-2. Similar to this observation, previous 
studies have shown that PS1/2 promote the degradation of β-catenin by facilitating its phosphorylation 
(28), and that, in hippocampal neurons, PS1/2 increase the turnover of the neuron-specific cell 
adhesion molecule telencephalin by enhancing autophagic vacuole-mediated catabolism (56, 57). Our 
results and these findings indicate a γ-secretase-independent function for PS1/2 in regulating the 
accumulation level of effector proteins. 
The molecular pathomechanism by which PS1/2 mutations cause AD is not entirely clear, 
although FAD-linked mutations are known to enhance the production of long, pathogenic Aβ peptides 
through altering γ-secretase cleavage by PS complexes (reviewed in 58). Oligomerized forms of Aβ 
have been implicated in the pathogenesis in AD due to both deleterious effects on synaptic plasticity 
and toxic effects that induce neuronal death (59, 60). In addition to neurotoxicity of Aβ, several other 
pathological conditions such as oxidative stress, impaired calcium homeostasis, and mitochondrial 
dysfunction are observed in AD brains (reviewed in 61). These apoptosis-inducing stimuli may 
 - 15 - 
accelerate the irreversible and pathological processes in AD brains, and mitochondria can act not only 
as mediators but also as amplifiers of apoptosis signaling. Our results suggest that FAD-linked 
mutations in PS1/2 lower the threshold for activation of mitochondria-mediated apoptosis pathways in 
neurons of individuals with FAD. In cases of sporadic AD, for which the primary causes are still 
unclear, yet unidentified factors besides PS mutations could contribute to disease progression by 
enhancing the pro-apoptotic activity of PS1/2. Therefore, blockers of endogenous binding between 
PS1/2 and FKBP38, such as polypeptides spanning the PS1/2 CTF sequences, might be beneficial in 
the treatment of AD by preventing the enhancement of apoptosis by PS1/2. 
MATERIAL AND METHODS 
Yeast two-hybrid screen 
The bait vector pGBKT7-PS1C, encoding the C-terminal sequence of PS1 fused to the 
GAL4 DNA binding domain, was generated by subcloning the PCR-amplified PS1 fragment into 
pGBKT7, which is free of autonomous β-galactosidase activity. Yeast two-hybrid screening was 
performed on a human HeLa cell cDNA library according to the manufacturer’s instructions (Clontech, 
San Diego, CA, USA). Briefly, yeast strain AH109 was cotransformed with pGBKT7-PS1C and 
pACT2 containing library cDNAs fused to the GAL4 transcription activation domain. The 
transformants were selected on plates lacking histidine, tryptophan, lysine, and leucine. Positive 
clones were identified after seven days, and yeast mating assays were performed to confirm the 
interaction in yeast. Candidate cDNAs for PS1-interacting proteins were isolated, sequenced, and 
analyzed using the BLASTN program. 
cDNA constructs, antibodies, and reagents 
Eukaryotic expression vectors for PS1 and PS2 were previously described (62). Constructs 
for various truncation mutants for PS1 and PS2 were prepared by subcloning the PCR-amplified 
fragments into pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). Expression vectors for FKBP38-Myc, 
FKBP51-Myc, FKBP52-Myc and CyP40-Myc were generated by subcloning the sequence-verified 
RT-PCR products into pcDNA4/Myc-His (Invitrogen). FKBP38 fused to GFP was subcloned into 
pEGFP-N1 (Clonetech). The FKBP38-HA and FKBP38ΔTM-HA constructs and the rabbit polyclonal 
antibody against the N-terminus of FKBP38 were prepared as described (33). Monoclonal antibodies 
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were purchased for PS1 CTF (Chemicon, Temecula, CA, USA), cytochrome c (BD Pharmingen, San 
Diego, CA, USA), adaptin-γ (Transduction Laboratories, Lexington, KY, USA), cyclooxygenase-IV 
(Molecular Probes, Eugene, OR, USA), HA (Roche Diagnostics, Mannheim, Germany), and GFP 
(Nacalai, Kyoto, Japan). The polyclonal antibodies were obtained for PS1 NTF (Zymed, South San 
Francisco, CA, USA), PS2 CTF (Cell Signaling, Beverly, CA, USA), APP (Sigma, St. Louis, MO, 
USA), and calnexin (Stressgen, San Diego, CA, USA). Polyclonal anti-PS2 NTF, anti-Hsp90, 
monoclonal anti-Myc tag (9E10), and anti-Bcl-2 antibodies were from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). DFK167 was purchased from Enzyme Systems Products (Livermore, CA, 
USA). DAPT and L-685,458 were obtained from Calbiochem (San Diego, CA, USA). Cycloheximide, 
staurosporine, A23187, rapamycin, and etoposide were from Sigma. 
Cell culture, cDNA transfection, RNAi, and mutant PS1-knockin mouse 
HEK293 cells and MEFs derived from PS1- and/or PS2-knockout mice (63) were cultured 
in Dulbecco’s modified Eagle medium containing 10% fetal bovine serum and 1% 
streptomycin/penicillin. Transfection of cDNA into HEK293 cells was carried out using 
Lipofectamine PLUS reagent (Invitrogen). RNAi using a duplex siRNA against FKBP38 was 
described (33). Retroviral infection of MEFs was performed as previously reported (64). Briefly, 
PLATE-E packaging cells were transfected with the pMXs vector carrying the cDNA encoding 
FKBP38, PS2, or PS2 CTFCAS using FuGene-6 (Roche Diagnostics). Culture media were collected two 
days after transfection for use as viral stocks. Viral transfection was carried out by incubating MEFs 
with viral stock containing 10 µg/ml Polybrene. One day after infection, the medium was replaced 
with fresh medium containing 10% fetal bovine serum. Infection efficiency was more than 95% in this 
study, as estimated from a control experiment using pMXs-β-galactosidase. 
 Generation and characterization of FAD-linked I213T-PS1-knockin mice was described 
previously (44). Brains were removed from two mice for each genotype (WT and heterozygous and 
homozygous mutants) and were homogenized with a Polytron PT1300D homogenizer (Kinematica, 
Littau-Luzern, Switzerland). Nuclei and cell debris were removed by centrifugation at 1,500g for 10 
min. The postnuclear supernatants were subjected to subcellular fractionation. 
Immunoblotting and immunoprecipitation 
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Cells were lysed in lysis buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 2 mM EDTA, 
10% glycerol, and a mixture of protease inhibitors) containing 1% 
3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonic acid (CHAPSO). Protein 
concentration was determined using the micro DC protein assay kit (BioRad, Hercules, CA, USA). 
Immunoblotting was performed as previously described (62). The same amount of proteins from cell 
lysates was loaded in each lane. For immunoprecipitation, lysates of cultured cells or murine brains 
were pre-cleared with protein A-Sepharose CL-4B (Amersham Biosciences, Uppsala, Sweden) and 
were then incubated overnight at 4ºC with the appropriate antibody and protein A-Sepharose. The 
immunoprecipitates were washed three times with lysis buffer and were analyzed by immunoblotting. 
Glycerol velocity gradient centrifugation 
Glycerol velocity gradient centrifugation was carried out as previously described (35). 
HEK293 cells were disrupted in a Dounce homogenizer, and nuclei and large cell debris were 
sedimented by centrifugation at 1,500g for 10 min. Vesicle pellets were prepared from the postnuclear 
supernatants by centrifugation at 100,000g for 1 h and then lysed in buffer containing 1% CHAPSO. 
The lysates were layered onto a 15% to 30% (w/v) linear continuous glycerol gradient and centrifuged 
at 36,000g for 18 h. Fractions were collected from the bottom to give 20 fractions of 600 µl. The first 
eight fractions from the bottom were discarded, and the remaining fractions were analyzed by 
immunoblotting. Ferritin (440 kDa), β amylase (200 kDa), lactate dehydrogenase (140 kDa) and 
bovine serum albumin (67 kDa) are used as molecular weight markers. 
Assessment of cell viability, apoptosis, and cytochrome c translocation 
MEFs were treated with vehicle (DMSO), 2 µM staurosporine, or 10 µg/ml A23187 for 24 
h in culture plates. Cell viability was evaluated by an MTT conversion assay. At the end of treatment 
period, 10 µl of MTT solution (5 mg/ml) was added to 100 µl of culture medium in each well of a 
96-well plate. After 4 h incubation, 100 µl of MTT solubilization solution (isopropanol with 0.04 N 
HCl) was added to each well and mixed. The absorbance (570 nm) in each well was measured with a 
plate reader. Apoptosis was quantified with an apoptosis detection kit (MBL, Nagoya, Japan). After 
staining with annexin V-fluorescein isothiocyanate (FITC) and PI, apoptotic cells showed green 
fluorescence, and dead cells showed both red and green fluorescence as visualized by fluorescence 
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microscopy. Both bright-field and fluorescence images were obtained from arbitrary selected areas for 
each well in the 24-well plate using an IX71 microscope (Olympus, Tokyo, Japan). The percentage of 
annexin V-FITC- and/or PI-positive cells was determined by direct cell counting. For each value, 
approximately 1000 cells were counted from 10 images. For the cytochrome c translocation assay, 
cells were harvested in a hypotonic buffer (20 mM HEPES, pH 7.4, 10 mM MgCl2, 42 mM KCl, and a 
mixture of protease inhibitors) and passed once through a 30-gauge needle. After sedimenting the 
crude nuclear fraction, the postnuclear supernatant was further centrifuged at 15,000g for 30 min to 
yield a crude membrane fraction. The supernatant was used as a cytosolic fraction. Both fractions were 
then subjected to immunoblotting with an anti-cytochrome c antibody. 
Semi-quantitative RT-PCR and pulse-chase experiment 
For semi-quantitative RT-PCR, total cellular RNA was isolated from MEFs using TRIzol 
reagent (Invitrogen). OneStep RT-PCR amplification (Qiagen, Valencia, CA, USA) was carried out 
with 100 ng total RNA and primer pairs specific for FKBP38, Bcl-2 or β-actin. Products were 
separated by electrophoresis on a 1.2% agarose gel, which was then stained with ethidium bromide. 
To identify the exponential amplification phase, 15, 20, 25, 30, and 35 PCR cycles were tested. 
For pulse-chase experiment, MEFs were incubated for 1 h in Met- and Cys-free DMEM 
(Invitrogen) and were then labeled for 1 h with 50 µCi/ml [35S] Met and [35S] Cys (ICN Biomedicals, 
Irvine, CA, USA). Media were then replaced with complete medium for indicated times, after which 
cells were lysed in lysis buffer. Lysates were subjected to immunoprecipitation with anti-FKBP38 or 
anti-Bcl-2 antibody, and the immunoprecipitates were separated by SDS-PAGE. Gels were dried and 
analyzed with an electronic autoradiography imager (Packard Instruments, Meriden, CT, USA). 
Assessment of subcellular localization of FKBP38 and Bcl-2 
For immunocytochemistry, cells were fixed with 4% paraformaldehyde for 15 min and then 
permeabilized with 0.1% Triton X-100 for 5 min. Nonspecific antibody binding was blocked by 
incubating cells with 5% normal goat serum for 1 h. Fixed cells were incubated overnight at 4°C with 
a primary antibody, followed by reaction for 2 h with Alexa488-conjugated secondary antibody 
(Molecular Probes). Mitochondria were stained with MitoTracker Red (Molecular Probes) according 
to the manufacturer’s instructions. Finally, the slides were analyzed with a LSM510 confocal 
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laser-scanning microscope (Zeiss, Oberkochen, Germany). 
Subcellular fractionation by iodixanol gradient centrifugation was performed according to a 
previously described method with some modifications (65). The same amount of protein from 
resuspended vesicle preparations was applied to the top of a 2.5% to 30% (v/v) linear iodixanol 
gradient (Axis-Shield, Oslo, Norway) and was separated by centrifugation for 3 h at 200,000g. 
Sequential 1-ml fractions were then collected from the bottom of the centrifuge tube and were 
analyzed by immunoblotting. 
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Figure legends 
Figure 1 
PS1/2 specifically interact with FKBP38. (A) Coimmunoprecipitation of transfected PS1/2 and 
FKBP38. HEK293 cells were transiently cotransfected with PS1 (left panels) or PS2 (right panels) 
together with FKBP38-Myc, CyP40-Myc, FKBP51-Myc, or FKBP52-Myc. Cell lysates (Input) and 
immunoprecipitates obtained with an anti-Myc antibody (IP) were analyzed by immunoblotting. (B) 
Coimmunoprecipitation of endogenous PS1/2 and FKBP38. Protein extracts from mouse brains were 
subjected to immunoprecipitation with preimmune serum or an antibody against PS1 CTF, PS2 CTF, 
Bcl-2, calnexin, or FKBP38. Total extract (Input) and immunoprecipitates were immunoblotted with 
an anti-FKBP38 antibody. (C) Coimmunoprecipitation of PS1/2 and FKBP38ΔTM. Lysates from 
HEK293 cells transiently transfected with FKBP38-HA and FKBP38ΔTM-HA were subjected to 
immunoprecipitation with an anti-PS1 CTF or anti-PS2 CTF antibody. Cell lysates (Input) and 
immunoprecipitates were immunoblotted with an anti-HA antibody. (D) Coimmunoprecipitation in 
lysates from PS1/2- and/or FKBP38-depleted cells. Cell lysates were prepared from native, PS1/2-null, 
FKBP38-knockdown (k/d), or PS1/2-null/FKBP38-k/d MEFs. Total cell lysates (Input) and 
immunoprecipitates with preimmune serum (P) or anti-Bcl-2 antibody (B) were immunoblotted with 
an antibody against PS1 CTF, PS2 CTF, FKBP38, or Bcl-2.  
 
Figure 2 
FKBP38 and Bcl-2 are incorporated into macromolecular complexes of PS1/2. (A) Glycerol velocity 
gradient centrifugation followed by immunoblotting for PS1, PS2, FKBP38, and Bcl-2. Extracts from 
native HEK293 cells were used for analysis of PS1, FKBP38, or Bcl-2, and PS2-transfected 
HEK293 cells were used for PS2 analysis. The positions of molecular weight markers are indicated at 
the top of the panel. Results are representative of three independent experiments. (B) 
Coimmunoprecipitation with anti-PS2 CTF antibody from fractionated samples in A. 
Immunoprecipitates were subjected to immunoblotting with an antibody against FKBP38, Bcl-2, or 
PS2 CTF. 
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Figure 3 
PS1 and PS2 sensitize MEFs to apoptosis. Native, PS1-null, PS2-null, and PS1/2-null MEFs were 
treated for 24 h with vehicle (DMSO), 2 µM staurosporine (STS), or 10 µg/ml A23187. (A) The 
relative viability was estimated by an MTT assay. Data represent the means ± SD (n = 24). *p < 0.001 
by one-way ANOVA with Dunnett’s post-hoc test. (B) The percentage of annexin V- and/or 
PI-positive apoptotic MEFs. Data represent the means ± SD (n = 3). *p < 0.001 by one-way ANOVA 
with Dunnett’s post-hoc test. (C) Cytochrome c translocation assay. Cytosol (C) and membrane (M) 
fractions from the treated MEFs were analyzed by immunoblotting with an anti-cytochrome c 
antibody. Results are representative of three independent experiments. 
 
Figure 4 
PS1/2 promote the degradation of FKBP38 and Bcl-2. (A) Immunoblotting of native and PS1/2-null 
MEF lysates for endogenous FKBP38, Bcl-2, and β-actin. Equal amounts of protein (20 µg) were 
loaded in each lane. (B) Semi-quantitative RT-PCR analysis of FKBP38 or Bcl-2 mRNA in native and 
PS1/2-null MEFs. PCR products amplified after 20 and 30 cycles are shown. RT-PCR for β-actin 
served as an internal standard. (C) Immunoblot analysis showing degradation of FKBP38 and Bcl-2 
proteins in native and PS1/2-null MEFs after treatment with the protein synthesis inhibitor 
cycloheximide (50 µg/ml). Equal amounts of protein (20 µg) were loaded in each lane. The intensity 
of the bands was determined by densitometry. The graphs show the average relative intensity from 
three independent blots. Error bars represent the SD. (D) Pulse-chase experiment for FKBP38 in 
native and PS1/2-null MEFs. Bands at a chase time = 0 represent the rates of translation. 
 
Figure 5 
FKBP38 is not a substrate for γ-secretase. (A) Culture media, cytosol fractions, and membrane 
fractions from native and PS1/2-null MEFs were immunoblotted with an anti-FKBP38 antibody. (B) 
HEK293 cells were treated with vehicle (DMSO) or the γ-secretase inhibitors DFK167 (100 µM), 
DAPT (2 µM), or L-685,458 (1 µM) for 24 h. Cell lysates were immunoblotted with an anti-FKBP38 
or anti-APP antibody. (C) HEK293 cells transiently transfected with FKBP38 fused to GFP 
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(FKBP38-GFP) were cultured in the absence or presence of DFK167 (100 µM) for 24 h. Cell lysates 
were immunoblotted with an anti-GFP antibody. 
 
Figure 6 
PS1/2 regulate the subcellular distribution of FKBP38 and Bcl-2. (A) Double fluorescence labeling 
confocal microscopy showing the localization of FKBP38 (green) and mitochondria (MitoTracker; 
red) in native and PS1/2-null MEFs. Merged images show mitochondrial localization of FKBP38 as 
yellow fluorescence. (B) Double-staining confocal images showing the localization of Bcl-2 (green) 
and mitochondria (MitoTracker; red). Mitochondrial Bcl-2 is shown in yellow fluorescence. (C) 
Subcellular fractionation by iodixanol gradient centrifugation of native and PS1/2-null MEFs. 
Fractionated samples (indicated at the bottom) were analyzed by immunoblotting with an antibody 
against PS1 CTF, FKBP38, or Bcl-2. The distribution patterns of the mitochondrial marker 
cyclooxygenase-IV (COX-IV), the ER marker calnexin, and the trans-Golgi network marker adaptin-γ 
are shown in the upper panels. (D) Iodixanol fractionation of FKBP38 knockdown (k/d) MEFs. Native 
and PS1/2-null MEFs were treated with a duplex siRNA against FKBP38 (FKBP38-k/d in native, and 
FKBP38-k/d in PS1/2-null, respectively), and the cell homogenates were subjected to iodixanol 
fractionation. Fractionated samples were immunoblotted with an anti-Bcl-2 antibody. Results are 
representative of three independent experiments. 
 
Figure 7 
Pro-apoptotic activity of PS1/2 correlates with a reduction in mitochondrial Bcl-2. (A) MTT assay of 
MEFs expressing various constructs of PS2 and/or FKBP38. WT PS2, WT PS2 + FKBP38, 
FAD-linked (N141I and M239V) PS2, or loss-of-function mutant (D366A) PS2 was transfected by a 
retrovirus into PS1/2-null MEFs. PS2 CTFCAS was transfected into native MEFs. Then, MEFs were 
treated for 24 h with vehicle (DMSO) or staurosporine (2 µM). Relative viability is shown. Results 
represent the means ± SD (n = 24). *p < 0.001 by one-way ANOVA with Dunnett’s post-hoc test. (B) 
Immunoblotting of total cell lysates from PS1/2-null, native, and PS2-overexpressing (OE) MEFs. 
Blots were probed with an antibody against PS2 CTF, PS1 CTF, FKBP38, Bcl-2, or β-actin. Equal 
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amounts of protein (20 µg) were loaded in each lane. (C) Subcellular fractionation by iodixanol 
gradient centrifugation of native MEFs and MEFs overexpressing WT PS2, WT PS2 + FKBP38, 
N141I-PS2, PS2 CTFCAS, or D366A-PS2. Fractionated samples were immunoblotted with anti-Bcl-2 
antibody. The distribution of organelle markers is shown in Figure 6C. The relative intensity of the 
bands for Bcl-2 in tentative mitochondrial fractions (lanes 1-5) and in whole lanes was determined by 
densitometry. The graph shows the average ratios of mitochondrial to total Bcl-2 from three 
independent blots. Error bars represent the SD. *p < 0.05 by one-way ANOVA with Dunnett’s 
post-hoc test. (D) Iodixanol fractionation followed by immunoblotting shows the distribution of 
transfected PS2 in PS1/2-null MEFs. (E) Iodixanol fractionation of brains from FAD-linked 
I213T-PS1-knockin mice. Brain homogenates were prepared from WT, heterozygous (Mut 
PS1-k/i-hetero), and homozygous (Mut-PS1-k/i-homo) mice. Fractionated samples were 
immunoblotted with an antibody against FKBP38 (left panels) or Bcl-2 (right panels). Results are 
representative of three independent experiments. 
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The abbreviations used 
PS, presenilin; 
FKBP, FK506-binding protein; 
AD, Alzheimer’s disease; 
FAD, familial Alzheimer’s disease; 
Aβ, amyloid β; 
APP, amyloid β-precursor protein; 
WT, wild-type; 
TPR, tetratricopeptide repeat; 
MEF, mouse embryonic fibroblast; 
HEK293 cell, human embryonic kidney 293 cell; 
ER, endoplasmic reticulum; 
FL, full length; 
NTF, N-terminal fragment; 
CTF, C-terminal fragment; 
CHAPSO, 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonic acid; 
MTT, 3-(4,5-dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide; 
RNAi, RNA interference; 
siRNA, small interfering RNA; 
FITC, fluorescein isothiocyanate; 
PI, propidium iodide; 
HA, haemagglutinin A; 
GFP, green fluorescent protein. 
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